These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 14657441

  • 1. Everolimus in cardiac-transplant recipients.
    Banas B, Böger C, Krämer B.
    N Engl J Med; 2003 Dec 04; 349(23):2271-2; author reply 2271-2. PubMed ID: 14657441
    [No Abstract] [Full Text] [Related]

  • 2. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
    Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P, RAD B253 Study Group.
    N Engl J Med; 2003 Aug 28; 349(9):847-58. PubMed ID: 12944570
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.
    Viganò M, Tuzcu M, Benza R, Boissonnat P, Haverich A, Hill J, Laufer G, Love R, Parameshwar J, Pulpón LA, Renlund D, Abeywickrama K, Cretin N, Starling RC, Eisen HJ, RAD B253 Study Group.
    J Heart Lung Transplant; 2007 Jun 28; 26(6):584-92. PubMed ID: 17543781
    [Abstract] [Full Text] [Related]

  • 5. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial.
    Valantine H.
    J Heart Lung Transplant; 2005 Apr 28; 24(4 Suppl):S191-5; discussion S210-1. PubMed ID: 15774321
    [Abstract] [Full Text] [Related]

  • 6. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation.
    Eisen H.
    Nephrol Dial Transplant; 2006 Jul 28; 21 Suppl 3():iii9-13. PubMed ID: 16815858
    [Abstract] [Full Text] [Related]

  • 7. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
    Lehmkuhl H, Hetzer R.
    J Heart Lung Transplant; 2005 Apr 28; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
    [Abstract] [Full Text] [Related]

  • 8. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.
    Lindenfeld J, Miller GG, Shakar SF, Zolty R, Lowes BD, Wolfel EE, Mestroni L, Page RL, Kobashigawa J.
    Circulation; 2004 Dec 21; 110(25):3858-65. PubMed ID: 15611389
    [No Abstract] [Full Text] [Related]

  • 9. Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference.
    Rothenburger M, Zuckermann A, Bara C, Hummel M, Strüber M, Hirt S, Lehmkuhl H, Certican Consensus Study Group.
    J Heart Lung Transplant; 2007 Apr 21; 26(4):305-11. PubMed ID: 17403469
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
    Schweiger M, Wasler A, Prenner G, Stiegler P, Stadlbauer V, Schwarz M, Tscheliessnigg K.
    Transpl Immunol; 2006 Jun 21; 16(1):46-51. PubMed ID: 16701176
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.
    Zuckermann A, Manito N, Epailly E, Fiane A, Bara C, Delgado JF, Lehmkuhl H, Ross H, Eisen H, Chapman J, Valantine H.
    J Heart Lung Transplant; 2008 Feb 21; 27(2):141-9. PubMed ID: 18267219
    [Abstract] [Full Text] [Related]

  • 14. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
    Zuckermann A.
    J Heart Lung Transplant; 2005 Apr 21; 24(4 Suppl):S206-9; discussion S210-1. PubMed ID: 15774324
    [Abstract] [Full Text] [Related]

  • 15. [Everolimus].
    Michels G, Hoppe UC.
    Dtsch Med Wochenschr; 2005 Oct 07; 130(40):2263-5. PubMed ID: 16208601
    [No Abstract] [Full Text] [Related]

  • 16. Everolimus: a review of its use in renal and cardiac transplantation.
    Dunn C, Croom KF.
    Drugs; 2006 Oct 07; 66(4):547-70. PubMed ID: 16597167
    [Abstract] [Full Text] [Related]

  • 17. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.
    Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A, O'Driscoll G, Macdonald P, Esmore D, Muller D, Faddy S.
    Circulation; 2004 Oct 26; 110(17):2694-700. PubMed ID: 15262845
    [Abstract] [Full Text] [Related]

  • 18. Cardiac-allograft vasculopathy.
    Avery RK.
    N Engl J Med; 2003 Aug 28; 349(9):829-30. PubMed ID: 12944567
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
    Tenderich G, Fuchs U, Zittermann A, Muckelbauer R, Berthold HK, Koerfer R.
    Clin Transplant; 2007 Aug 28; 21(4):536-43. PubMed ID: 17645716
    [Abstract] [Full Text] [Related]

  • 20. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors.
    Eisen H, Kobashigawa J, Starling RC, Valantine H, Mancini D.
    Transplant Proc; 2005 May 28; 37(4 Suppl):4S-17S. PubMed ID: 15809102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.